文献速递心脑血管急症复苏、休克与脓毒症

胺碘酮和/或利多卡因用于心脏骤停:一项贝叶斯网络Meta分析

Amiodarone and/or lidocaine for cardiac arrest: A Bayesian network meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-07-05
一句话结论心脏骤停时,利多卡因在提高入院存活和出院存活方面效果最佳,胺碘酮则与更有利的神经功能结局相关。

该贝叶斯网络Meta分析纳入9项研究,评估胺碘酮和/或利多卡因对心脏骤停患者存活至入院/24小时、存活至出院及神经功能结局的影响。头对头研究显示,胺碘酮(OR 2.96,95%CrI 1.02-8.53)和利多卡因(OR 3.12,95%CrI 1.08-9.98)在存活至入院/24小时方面均优于两药联合。与安慰剂相比,胺碘酮(OR 1.18,95%CrI 1.03-1.35)和利多卡因(OR 1.22,95%CrI 1.06-1.41)均提高出院存活率;胺碘酮(OR 1.20,95%CrI 1.02-1.41)在神经功能结局方面显著优于安慰剂。SUCRA显示利多卡因对入院存活(84.1%)和出院存活(88.4%)最有效,胺碘酮与更有利的神经功能结局相关(88.2%)。

要点

  • 与安慰剂相比,胺碘酮提高出院存活(OR 1.18,95%CrI 1.03-1.35),利多卡因提高出院存活(OR 1.22,95%CrI 1.06-1.41)。
  • 头对头研究中,胺碘酮(OR 2.96,95%CrI 1.02-8.53)和利多卡因(OR 3.12,95%CrI 1.08-9.98)在存活至入院/24小时方面均优于两药联合。
  • 胺碘酮在神经功能结局方面显著优于安慰剂(OR 1.20,95%CrI 1.02-1.41)。
  • SUCRA显示利多卡因对入院存活(84.1%)和出院存活(88.4%)最有效,胺碘酮与更有利的神经功能结局相关(88.2%)。

适用人群与场景

  • 心脏骤停患者(基于纳入的9项研究)

研究设计与关键结果

  • 研究类型:贝叶斯网络Meta分析,纳入9项研究,检索至2020年1月21日。
  • 主要终点为存活至出院,次要终点为存活至入院/24小时和有利神经功能结局。
  • 头对头研究:胺碘酮(OR 2.96,95%CrI 1.02-8.53)和利多卡因(OR 3.12,95%CrI 1.08-9.98)在存活至入院/24小时方面优于两药联合。
  • 与安慰剂相比,胺碘酮(OR 1.18,95%CrI 1.03-1.35)和利多卡因(OR 1.22,95%CrI 1.06-1.41)提高出院存活率。
  • 胺碘酮在有利神经功能结局方面显著优于安慰剂(OR 1.20,95%CrI 1.02-1.41)。
  • 其他配对比较无显著差异。
  • SUCRA:利多卡因对入院存活(84.1%)和出院存活(88.4%)最有效,胺碘酮与更有利的神经功能结局相关(88.2%)。

证据类型、等级与局限

  • 证据类型:贝叶斯网络Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:利多卡因对入院存活和出院存活效果最佳,胺碘酮与更有利的神经功能结局相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Although available studies have not demonstrated that antiarrhythmic drugs could increase long-term survival or survival with favorable neurological outcome, some studies have shown that the rate of hospital admission is higher with amiodarone or lidocaine than with placebo. To study the effects of antiarrhythmic drugs during cardiac arrest, a meta-analysis was conducted to assess the efficacy of amiodarone and/or lidocaine.

METHODS: We searched studies from inception until Jan 21, 2020. The primary endpoint was survival to hospital discharge in cardiac arrest, and the secondary endpoints were survival to hospital admission/24 h and favorable neurological outcome.

RESULTS: A total of 9 studies were included. In head-to-head studies, amiodarone (odds ratio [OR] 2.96, 95% credible interval [CrI] 1.02-8.53) and lidocaine (OR 3.12, 95% CrI 1.08-9.98) had superior effects on survival to hospital admission/24 h compared to the combination of the two drugs. In terms of survival to hospital discharge, amiodarone (OR 1.18, 95% CrI 1.03-1.35) and lidocaine (OR 1.22, 95% CrI 1.06-1.41) were more effective than placebo. Amiodarone (OR 1.20, 95% CrI 1.02-1.41) was significantly better than placebo in favorable neurological outcome. However, there was no significant difference in other pairwise comparisons. The surface under cumulative ranking curve (SUCRA) revealed that lidocaine was the most effective therapy for survival to hospital admission (84.1%) and discharge (88.4%), while amiodarone was associated with a more favorable neurological outcome (88.2%).

CONCLUSIONS: Lidocaine had the best effect on both survival to hospital admission and discharge, while amiodarone was associated with a more favorable neurological outcome.

TRIAL REGISTRATION: This study is registered with PROSPERO, number CRD42020171049.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhao H, Fan K, Feng G, et al. Amiodarone and/or lidocaine for cardiac arrest: A Bayesian network meta-analysis. Am J Emerg Med. 2020. PMID: 33071078. doi:10.1016/j.ajem.2020.06.074

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。